LTR Pharma is a Clinical Stage Biopharmaceutical Company
Erectile dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.
SDS-089 provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects
LTR Pharma is commercializing a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SDS-089 with fast-track US NDA Filing within 2 years
worldwide expected cases by 2025
projected global market value 2024
ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.